OFDI-Guided Stentless PCI for Erosion-Related STEMI Unmasking Antiphospholipid Syndrome Authors: Atsuhiro Saito, Yoshinari Enomoto, Ryo Terashima, Wataru Miyake, Masaya Yamamoto, Hisao Hara, Yukio Hiroi Published: 2026 ABSTRACT AbstractBackgroundAntiphospholipid syndrome (APS) accounts for 2.8% to 5.5% of acute myocardial infarctions in young adults, yet it is often unrecognized at presentation.Case SummaryA 25-year-old man presented with anterior ST-segment elevation myocardial infarction, ventricular fibrillation, and cardiogenic shock. Angiography revealed a 99% proximal left anterior descending artery stenosis. Intracoronary imaging revealed an organized thrombus-dominant lesion without plaque rupture, suggestive of plaque erosion. Given his young age and large diagonal branch at risk, a prolonged perfusion-balloon inflation was used to achieve TIMI flow grade 3. Persistent antiphospholipid antibody positivity at ≥12 weeks confirmed definite APS; warfarin monotherapy was initiated.DiscussionPost hoc confirmation of APS guided long-term vitamin K antagonist therapy, underscoring the value of thrombophilia screening in young-onset myocardial infarction.Take-Home MessagesStentless revascularization is a reasonable option in young patients with myocardial infarction and imaging features of plaque erosion. APS should be screened to guide appropriate anticoagulation therapy.Key Words: antiphospholipid antibodies, optical frequency domain imaging, perfusion balloon, plaque erosion, stentless revascularization, young-onset myocardial infarction Myocardial infarction (MI) in young adults requires the investigation of nonatherosclerotic mechanisms, including acquired thrombophilia. Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by persistent antiphospholipid antibodies (aPL) and recurrent vascular thrombosis. aPL is detected in approximately 11% of patients hospitalized with MI, and an estimated 2.8% to 5.5% of MI cases in young individuals are attributable to APS.1,2 Intravascular imaging with optical coherence tomography or optical frequency domain imaging (OFDI) can differentiate plaque rupture from plaque erosion, enabling mechanism-based treatment decisions. The EROSION study and its subsequent follow-up demonstrated that in patients with acute coronary syndrome caused by plaque erosion, antithrombotic therapy without stenting is an effective alternative to conventional stent-based percutaneous coronary intervention (PCI).3,4 We present the case of a 25-year-old man with anterior ST-segment elevation MI (STEMI) and cardiogenic shock, in whom OFDI identified an erosion-related organized thrombus and guided a stentless strategy; subsequent work-up confirmed APS, underscoring thrombophilia screening in young-onset MI. Take-Home Messages •In young patients with ST-segment elevation myocardial infarction and intracoronary imaging findings suggestive of plaque erosion rather than rupture, an optical frequency domain imaging–guided stentless revascularization strategy may represent a reasonable treatment option, particularly when stent avoidance is desirable because of patient age, cumulative stent-related risks, or anatomical considerations such as side-branch preservation. In young patients with ST-segment elevation myocardial infarction and intracoronary imaging findings suggestive of plaque erosion rather than rupture, an optical frequency domain imaging–guided stentless revascularization strategy may represent a reasonable treatment option, particularly when stent avoidance is desirable because of patient age, cumulative stent-related risks, or anatomical considerations such as side-branch preservation. •Furthermore, APS should be actively considered and investigated in young patients presenting with myocardial infarction, especially in the absence of conventional cardiovascular risk factors. Furthermore, APS should be actively considered and investigated in young patients presenting with myocardial infarction, especially in the absence of conventional cardiovascular risk factors. •Early recognition of APS is critical because failure to identify the underlying thrombophilic disorder may lead to suboptimal antithrombotic management and increase the risk of recurrent arterial thrombotic events. Early recognition of APS is critical because failure to identify the underlying thrombophilic disorder may lead to suboptimal antithrombotic management and increase the risk of recurrent arterial thrombotic events. Case Presentation History of presentation A previously healthy 25-year-old man presented with 2 hours of crushing chest pain. On arrival, he was diaphoretic and tachypneic, with a blood pressure of 150/110 mm Hg. The 12-lead electrocardiogram showed extensive anterior ST-segment elevation (Figure 1). During preparation, he developed ventricular fibrillation requiring immediate resuscitation and was transferred to the catheterization laboratory. Admission 12-Lead Electrocardiogram Admission 12-lead electrocardiogram showing anterior ST-segment elevation with reciprocal inferior ST-segment depression. Past medical history The patient had no prior cardiovascular or autoimmune diagnoses; no history of diabetes mellitus, hypertension, or dyslipidemia; no history of smoking; and no family history of premature coronary artery disease. His body mass index was 33.9 kg/m2. Differential diagnosis The differential causes of STEMI include atherosclerotic plaque rupture, prothrombotic coronary thrombosis (eg, APS), coronary embolism, spontaneous coronary artery dissection, and severe vasospasm. Investigations Immediate coronary angiography revealed 99% stenosis of the proximal left anterior descending artery (LAD, segment 6) with thrombus translucency (Figure 2A). A large diagonal branch originated from the culprit segment. Manual aspiration thrombectomy was performed initially to secure the lumen, and although no visible thrombus was retrieved, postaspiration angiography showed a reduced thrombus burden. With the establishment of a safer lumen, OFDI was performed (Figure 3A). On OFDI, the culprit lesion showed a layered, signal-rich appearance consistent with an organized thrombus, without the abrupt signal attenuation that characterizes a lipid pool. No definite fibrous-cap rupture was identified on OFDI, and the adjacent coronary segments were free of atherosclerotic plaque. A definitive diagnosis of plaque erosion requires histology; our designation is therefore a presumptive, imaging-based inference. Nonetheless, several features argued against plaque rupture: 1) the absence of a discernible fibrous-cap rupture; 2) the absence of OFDI signal attenuation indicative of a lipid-rich plaque, favoring an organized thrombus over a ruptured atheroma; and 3) the absence of atherosclerotic disease elsewhere in the coronary tree, which makes isolated, single-site lipid accumulation culminating in cap rupture improbable in a 25-year-old man without a family history of premature coronary disease. We therefore considered the lesion most consistent with plaque erosion rather than rupture. Coronary Angiography Before and After Stentless Percutaneous Coronary Intervention (A) Initial angiography showing 99% stenosis of the proximal left anterior descending artery with an intraluminal filling defect consistent with thrombus. (B) Final angiography showing restoration of TIMI flow grade 3 after prolonged perfusion-balloon inflations without stent implantation. (C) Follow-up angiography on day 14 demonstrating a widely patent left anterior descending artery with no residual stenosis and preserved TIMI flow grade 3 after stentless revascularization. Optical Frequency-Domain Imaging of the Culprit Lesion Before and After Balloon Therapy (A) Preballoon imaging after aspiration thrombectomy demonstrating an organized thrombus with layered tissue of heterogeneous optical density (double-headed arrow), clearly demarcated from the underlying plaque, without disruption of the luminal surface. (B) Postballoon imaging showing an increased lumen area (minimum lumen area, 6.5 mm2) and no dissection, indicating reduced thrombus burden. Management (medical/interventions) Given the evolving cardiogenic shock and the anticipated need for prolonged thrombus management, a percutaneous microaxial left ventricular assist device was inserted via the left femoral artery before PCI to provide hemodynamic stabilization and left ventricular unloading. The revascularization strategy was guided by the OFDI findings. As OFDI indicated a thrombus-dominant lesion without definite fibrous-cap rupture or a high-risk lipid-rich plaque, a stentless approach was adopted. A 3.5 × 20-mm perfusion balloon catheter was used for multiple prolonged inflations to reduce the thrombus burden and restore the lumen while maintaining some distal coronary perfusion. Repeat OFDI confirmed successful thrombus reduction with adequate luminal gain (minimum lumen area, 6.5 mm2) (Figure 3B), and the final angiogram demonstrated TIMI flow grade 3 in the LAD, with no jeopardization of the diagonal branch (Figure 2B). The periprocedural antithrombotic regimen initially included aspirin (100 mg/d) and prasugrel (3.75 mg/d), the standard maintenance dose approved for patients undergoing PCI in Japan. Initial laboratory testing revealed lupus anticoagulant (LA) positivity (ratio, 2.6), suggesting the presence of an underlying thrombophilic disorder. On confirmation of LA positivity on hospital day 5 and considering the suspected APS-related prothrombotic milieu and the stentless result, the therapy was transitioned to warfarin monotherapy for long-term anticoagulation. This transition aligned with the current evidence favoring vitamin K antagonists over direct oral anticoagulants for arterial thrombosis in APS.5,6 The stentless strategy was based on OFDI-identified erosion morphology and the anatomical and age-related considerations described above, not on a known APS diagnosis, which was confirmed post hoc. Outcome and follow-up Transthoracic echocardiography during recovery showed improved left ventricular systolic function compared with the immediate postreperfusion study; the peak creatine kinase level was 1,452 U/L. Impella support was maintained for 3 days given the risk of recurrent hemodynamic deterioration after extensive anterior STEMI with ventricular fibrillation and shock. On day 14, a repeat coronary angiography confirmed a widely patent LAD with no residual stenosis (Figure 2C). The patient was discharged on day 16 on warfarin therapy with international normalized ratio–guided management. At 3-month follow-up, the patient remained asymptomatic. Repeat aPL testing confirmed persistent positivity (LA ratio 1.9, anticardiolipin IgG 21.1 U/mL, anti–β2-glycoprotein I 1.0 U/mL), establishing the definitive diagnosis of APS and reinforcing the long-term anticoagulation strategy. Discussion This case illustrates a mechanism-based approach to revascularization in a young patient with anterior STEMI and cardiogenic shock, in whom OFDI findings suggested plaque erosion rather than rupture. Plaque rupture involves a large lipid core with a disrupted fibrous cap and often requires stent implantation to scaffold the disrupted vessel wall and prevent acute recoil. In contrast, plaque erosion is characterized by superficial endothelial disruption over an intact fibrous cap, with a superimposed thrombus as the primary cause of lumen compromise. Thrombus management alone can restore adequate luminal dimensions without using a permanent metallic scaffold.4,7,8 The rationale for stent avoidance in the present case was 3-fold. First, OFDI confirmed that the culprit was a thrombus-dominant lesion with no significant underlying atherosclerotic plaques requiring structural support. Second, in a 25-year-old patient, stent implantation commits the patient to lifetime stent-related risk. Pooled randomized-trial data show that stent-related events, including target-lesion revascularization and stent thrombosis, accrue at roughly 2% to 3% per year beyond 1 year without plateau through ≥5 years, regardless of stent type;7 over several decades of life expectancy, this cumulative risk is substantial. Third, a large diagonal branch arose from the culprit segment, and stent deployment across this bifurcation could have jailed the side branch, potentially causing periprocedural myocardial injury or compromising future access. Had a large residual thrombus burden persisted with failure to achieve TIMI flow grade 3 despite aspiration thrombectomy and prolonged perfusion-balloon inflation, bailout drug-eluting stent implantation would have been the default strategy. A poorly perfused vessel with a substantial residual thrombus carries a high risk of rethrombosis and reocclusion; therefore, stent implantation may be necessary to secure a durable lumen and restore antegrade flow. In the setting of cardiogenic shock, prompt restoration of coronary flow and patient survival take precedence over the longer-term objective of stent avoidance. A drug-coated balloon was not used because repeat OFDI showed adequate luminal gain without flow-limiting dissection or residual stenosis requiring antiproliferative therapy in this thrombus-dominant lesion. Impella support was instituted before PCI to stabilize hemodynamics, giving the operator time for intravascular imaging and a thrombus-focused strategy. Recent randomized data support the use of microaxial pump support in infarct-related cardiogenic shock, although device-related complications require careful patient selection.9 The diagnosis of definite APS, established post hoc by persistent aPL positivity at ≥12 weeks, was not known at the time of the index PCI and therefore did not influence the revascularization decision. However, it profoundly influenced the long-term antithrombotic strategy. In APS-associated arterial thrombosis, vitamin K antagonist therapy is preferred over direct oral anticoagulants based on randomized evidence and meta-analytic data demonstrating higher recurrence rates with rivaroxaban.5,6 The stentless result facilitated an early transition from dual antiplatelet therapy to warfarin monotherapy, avoiding the combined bleeding risk of the triple therapy (anticoagulant plus dual antiplatelets) that would have been required if a stent had been placed. APS should be considered in the differential diagnosis of young-onset acute myocardial infarction, particularly when intravascular imaging reveals nonatherosclerotic mechanisms. APS-related coronary thrombosis may occur without conventional risk factors; prompt aPL screening enables disease-specific anticoagulation and may prevent recurrent thrombotic events. Conclusions In a young patient with APS-related anterior STEMI and cardiogenic shock, OFDI clarified a thrombus-dominant mechanism and supported a stentless, imaging-guided strategy using prolonged perfusion-balloon inflation under Impella support. This approach avoided coronary stent placement in the prothrombotic milieu and facilitated the transition to warfarin monotherapy once persistent LA positivity raised suspicion for APS. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Visual SummaryTimeline of Case PresentationTimelineEventsDay 1A 25-year-old man presented with anterior STEMI and developed ventricular fibrillation, requiring resuscitation. Urgent angiography revealed 99% stenosis of the proximal LAD. OFDI showed organized thrombus without plaque rupture. An Impella CP was inserted for hemodynamic support. Stentless PCI was performed using manual aspiration and prolonged perfusion-balloon inflations, achieving TIMI flow grade 3.Day 3Hemodynamics stabilized, and the Impella device was successfully removed.Day 5Lupus anticoagulant positivity was confirmed. Antithrombotic therapy was switched from dual antiplatelet therapy to warfarin monotherapy to target the underlying coagulopathy.Day 14Repeat coronary angiography demonstrated a widely patent LAD with no residual stenosis, confirming the efficacy of the stentless strategy.Day 16The patient was discharged on warfarin with no further complications.Follow-upHe remained asymptomatic. Repeat serological testing confirmed persistent antiphospholipid antibodies, establishing the definitive diagnosis of antiphospholipid syndrome. Long-term warfarin therapy was continued.LAD = left anterior descending artery; OFDI = optical frequency domain imaging; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction. Timeline of Case Presentation LAD = left anterior descending artery; OFDI = optical frequency domain imaging; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.